Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 28.08
(5.05%)
USD 28.08
(5.05%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 778.51 Million USD | 35.87% |
| 2022 | 573 Million USD | -28.29% |
| 2021 | 799 Million USD | 11.44% |
| 2020 | 717 Million USD | -35.92% |
| 2019 | 1.11 Billion USD | 87.17% |
| 2018 | 597.85 Million USD | 349.44% |
| 2017 | 133.02 Million USD | 5683.57% |
| 2016 | 2.3 Million USD | 105.96% |
| 2015 | -38.58 Million USD | -39.87% |
| 2014 | -27.59 Million USD | 24.92% |
| 2013 | -36.74 Million USD | 34.85% |
| 2012 | -56.4 Million USD | -156.93% |
| 2011 | 99.08 Million USD | -8.65% |
| 2010 | 108.47 Million USD | -10.8% |
| 2009 | 121.6 Million USD | 13.44% |
| 2008 | 107.19 Million USD | 53.96% |
| 2007 | 69.62 Million USD | 183.8% |
| 2006 | 24.53 Million USD | -38.87% |
| 2005 | 40.13 Million USD | -5.84% |
| 2004 | 42.62 Million USD | -14.73% |
| 2003 | 49.99 Million USD | -37.65% |
| 2002 | 80.17 Million USD | 50.51% |
| 2001 | 53.27 Million USD | 24.5% |
| 2000 | 42.79 Million USD | 9.44% |
| 1999 | 39.1 Million USD | -10.11% |
| 1998 | 43.5 Million USD | 21.85% |
| 1997 | 35.7 Million USD | 41.67% |
| 1996 | 25.2 Million USD | 59.49% |
| 1995 | 15.8 Million USD | 13.67% |
| 1994 | 13.9 Million USD | 234.95% |
| 1993 | -10.3 Million USD | -196.26% |
| 1992 | 10.7 Million USD | 305.77% |
| 1991 | -5.2 Million USD | -116.67% |
| 1990 | -2.4 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 111.69 Million USD | -65.25% |
| 2024 Q2 | 215.5 Million USD | 92.94% |
| 2023 Q3 | 142 Million USD | -23.24% |
| 2023 Q4 | 321.44 Million USD | 126.37% |
| 2023 FY | 778.51 Million USD | 35.87% |
| 2023 Q1 | 130 Million USD | -12.16% |
| 2023 Q2 | 185 Million USD | 42.31% |
| 2022 Q1 | 137.74 Million USD | -68.55% |
| 2022 Q2 | 129.04 Million USD | -6.32% |
| 2022 Q3 | 158.25 Million USD | 22.63% |
| 2022 Q4 | 148 Million USD | -6.48% |
| 2022 FY | 573 Million USD | -28.29% |
| 2021 FY | 799 Million USD | 11.44% |
| 2021 Q1 | 109.02 Million USD | -62.01% |
| 2021 Q2 | 122.79 Million USD | 12.62% |
| 2021 Q4 | 438 Million USD | 236.89% |
| 2021 Q3 | 130.01 Million USD | 5.88% |
| 2020 Q1 | 130.81 Million USD | -73.46% |
| 2020 FY | 717 Million USD | -35.92% |
| 2020 Q2 | 142.52 Million USD | 8.95% |
| 2020 Q3 | 156.99 Million USD | 10.15% |
| 2020 Q4 | 287 Million USD | 82.81% |
| 2019 FY | 1.11 Billion USD | 87.17% |
| 2019 Q1 | 296.17 Million USD | 54.79% |
| 2019 Q3 | 166.92 Million USD | 2.41% |
| 2019 Q2 | 163 Million USD | -44.96% |
| 2019 Q4 | 493 Million USD | 195.34% |
| 2018 Q2 | 15.91 Million USD | -60.55% |
| 2018 Q4 | 191.33 Million USD | 281.6% |
| 2018 FY | 597.85 Million USD | 349.44% |
| 2018 Q3 | 50.14 Million USD | 215.01% |
| 2018 Q1 | 40.35 Million USD | -8.32% |
| 2017 FY | 133.02 Million USD | 5683.57% |
| 2017 Q1 | 27.66 Million USD | -53.27% |
| 2017 Q4 | 44.01 Million USD | 8.15% |
| 2017 Q3 | 40.69 Million USD | 97.12% |
| 2017 Q2 | 20.64 Million USD | -25.37% |
| 2016 Q4 | 59.19 Million USD | 125.12% |
| 2016 Q2 | -39.1 Million USD | 11.31% |
| 2016 Q3 | 26.29 Million USD | 167.25% |
| 2016 FY | 2.3 Million USD | 105.96% |
| 2016 Q1 | -44.09 Million USD | 11.39% |
| 2015 Q4 | -49.76 Million USD | -26.34% |
| 2015 Q1 | -1.86 Million USD | -111.02% |
| 2015 Q2 | 52.42 Million USD | 2912.29% |
| 2015 Q3 | -39.38 Million USD | -175.14% |
| 2015 FY | -38.58 Million USD | -39.87% |
| 2014 Q2 | -2.18 Million USD | 91.35% |
| 2014 FY | -27.59 Million USD | 24.92% |
| 2014 Q4 | 16.9 Million USD | 199.32% |
| 2014 Q1 | -25.28 Million USD | -66.56% |
| 2014 Q3 | -17.02 Million USD | -678.02% |
| 2013 Q3 | -22.07 Million USD | -386.34% |
| 2013 FY | -36.74 Million USD | 34.85% |
| 2013 Q4 | -15.18 Million USD | 31.23% |
| 2013 Q2 | -4.53 Million USD | -189.92% |
| 2013 Q1 | 5.04 Million USD | 122.06% |
| 2012 Q3 | -24.57 Million USD | -151.91% |
| 2012 Q1 | 23.23 Million USD | -28.29% |
| 2012 Q4 | -22.88 Million USD | 6.87% |
| 2012 FY | -56.4 Million USD | -156.93% |
| 2012 Q2 | 47.34 Million USD | 103.74% |
| 2011 Q4 | 32.4 Million USD | 56.44% |
| 2011 FY | 99.08 Million USD | -8.65% |
| 2011 Q1 | 21.14 Million USD | -19.96% |
| 2011 Q2 | 24.82 Million USD | 17.38% |
| 2011 Q3 | 20.71 Million USD | -16.56% |
| 2010 FY | 108.47 Million USD | -10.8% |
| 2010 Q4 | 26.42 Million USD | -7.7% |
| 2010 Q2 | 23.5 Million USD | -21.46% |
| 2010 Q1 | 29.92 Million USD | -7.24% |
| 2010 Q3 | 28.62 Million USD | 21.79% |
| 2009 FY | 121.6 Million USD | 13.44% |
| 2009 Q3 | 26.77 Million USD | -13.62% |
| 2009 Q2 | 30.99 Million USD | -1.85% |
| 2009 Q4 | 32.26 Million USD | 20.51% |
| 2009 Q1 | 31.57 Million USD | 52.83% |
| 2008 Q2 | 32.96 Million USD | 54.36% |
| 2008 Q4 | 20.66 Million USD | -35.87% |
| 2008 FY | 107.19 Million USD | 53.96% |
| 2008 Q1 | 21.35 Million USD | -13.64% |
| 2008 Q3 | 32.21 Million USD | -2.26% |
| 2007 Q3 | 38.63 Million USD | 913.14% |
| 2007 FY | 69.62 Million USD | 183.8% |
| 2007 Q1 | 2.45 Million USD | -79.49% |
| 2007 Q2 | 3.81 Million USD | 55.63% |
| 2007 Q4 | 24.72 Million USD | -35.99% |
| 2006 FY | 24.53 Million USD | -38.87% |
| 2006 Q4 | 11.94 Million USD | 267.2% |
| 2006 Q3 | 3.25 Million USD | -25.65% |
| 2006 Q2 | 4.37 Million USD | -11.76% |
| 2006 Q1 | 4.95 Million USD | -66.14% |
| 2005 Q3 | 7.45 Million USD | -29.59% |
| 2005 Q4 | 14.64 Million USD | 96.31% |
| 2005 Q2 | 10.59 Million USD | 42.33% |
| 2005 FY | 40.13 Million USD | -5.84% |
| 2005 Q1 | 7.44 Million USD | -34.63% |
| 2004 FY | 42.62 Million USD | -14.73% |
| 2004 Q1 | 12.3 Million USD | 26.85% |
| 2004 Q2 | 9.84 Million USD | -20.0% |
| 2004 Q3 | 9.09 Million USD | -7.62% |
| 2004 Q4 | 11.38 Million USD | 25.21% |
| 2003 Q4 | 9.69 Million USD | -14.12% |
| 2003 Q2 | 15.01 Million USD | 7.41% |
| 2003 FY | 49.99 Million USD | -37.65% |
| 2003 Q1 | 13.98 Million USD | -36.04% |
| 2003 Q3 | 11.29 Million USD | -24.79% |
| 2002 Q1 | 17.95 Million USD | -17.41% |
| 2002 Q4 | 21.85 Million USD | 7.68% |
| 2002 Q3 | 20.3 Million USD | 1.19% |
| 2002 Q2 | 20.06 Million USD | 11.7% |
| 2002 FY | 80.17 Million USD | 50.51% |
| 2001 FY | 53.27 Million USD | 24.5% |
| 2001 Q1 | 4.63 Million USD | -41.62% |
| 2001 Q4 | 21.74 Million USD | 12.64% |
| 2001 Q3 | 19.3 Million USD | 154.27% |
| 2001 Q2 | 7.59 Million USD | 63.87% |
| 2000 Q4 | 7.93 Million USD | -56.59% |
| 2000 Q1 | 4.05 Million USD | -57.33% |
| 2000 Q3 | 18.28 Million USD | 161.7% |
| 2000 Q2 | 6.98 Million USD | 72.3% |
| 2000 FY | 42.79 Million USD | 9.44% |
| 1999 Q3 | 10.6 Million USD | 47.22% |
| 1999 FY | 39.1 Million USD | -10.11% |
| 1999 Q4 | 9.5 Million USD | -10.38% |
| 1999 Q1 | 6.6 Million USD | -13.16% |
| 1999 Q2 | 7.2 Million USD | 9.09% |
| 1998 Q3 | 19.8 Million USD | 241.38% |
| 1998 Q4 | 7.6 Million USD | -61.62% |
| 1998 Q2 | 5.8 Million USD | 0.0% |
| 1998 Q1 | 5.8 Million USD | -38.3% |
| 1998 FY | 43.5 Million USD | 21.85% |
| 1997 FY | 35.7 Million USD | 41.67% |
| 1997 Q2 | 5.8 Million USD | 26.09% |
| 1997 Q3 | 12.6 Million USD | 117.24% |
| 1997 Q1 | 4.6 Million USD | -28.13% |
| 1997 Q4 | 9.4 Million USD | -25.4% |
| 1996 Q4 | 6.4 Million USD | 25.49% |
| 1996 Q1 | 6.4 Million USD | 88.24% |
| 1996 FY | 25.2 Million USD | 59.49% |
| 1996 Q3 | 5.1 Million USD | 8.51% |
| 1996 Q2 | 4.7 Million USD | -26.56% |
| 1995 Q3 | 3.7 Million USD | 12.12% |
| 1995 Q4 | 3.4 Million USD | -8.11% |
| 1995 FY | 15.8 Million USD | 13.67% |
| 1995 Q2 | 3.3 Million USD | 26.92% |
| 1995 Q1 | 2.6 Million USD | 230.0% |
| 1994 Q2 | 3.1 Million USD | 19.23% |
| 1994 Q3 | 3.2 Million USD | 3.23% |
| 1994 Q4 | -2 Million USD | -162.5% |
| 1994 FY | 13.9 Million USD | 234.95% |
| 1994 Q1 | 2.6 Million USD | -10.34% |
| 1993 Q2 | 3.2 Million USD | 18.52% |
| 1993 Q4 | 2.9 Million USD | -12.12% |
| 1993 FY | -10.3 Million USD | -196.26% |
| 1993 Q1 | 2.7 Million USD | -85.64% |
| 1993 Q3 | 3.3 Million USD | 3.13% |
| 1992 FY | 10.7 Million USD | 305.77% |
| 1992 Q2 | -2.3 Million USD | 23.33% |
| 1992 Q1 | -3 Million USD | 9.09% |
| 1992 Q3 | -3 Million USD | -30.43% |
| 1992 Q4 | 18.8 Million USD | 726.67% |
| 1991 Q2 | 1.7 Million USD | 525.0% |
| 1991 Q3 | -1.2 Million USD | -170.59% |
| 1991 Q4 | -3.3 Million USD | -175.0% |
| 1991 FY | -5.2 Million USD | -116.67% |
| 1991 Q1 | -400 Thousand USD | -180.0% |
| 1990 Q3 | 500 Thousand USD | 0.0% |
| 1990 Q4 | 500 Thousand USD | 0.0% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 FY | -2.4 Million USD | 0.0% |
| 1990 Q2 | 500 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 94.886% |
| Dynavax Technologies Corporation | 182.11 Million USD | -327.48% |
| Illumina, Inc. | 2.74 Billion USD | 71.628% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 85.14% |
| Biogen Inc. | 7.3 Billion USD | 89.339% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 8238.344% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 64.108% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 28.772% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -48.645% |
| Waters Corporation | 1.76 Billion USD | 55.796% |
| Perrigo Company plc | 1.68 Billion USD | 53.671% |
| uniQure N.V. | 2.21 Million USD | -35047.359% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -4395.144% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -115.041% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 248826.518% |
| bluebird bio, Inc. | -4.03 Million USD | 19417.965% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -5162.363% |
| Imunon, Inc. | -720 Thousand USD | 108226.194% |
| Myriad Genetics, Inc. | 476.4 Million USD | -63.416% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 57.859% |
| Nektar Therapeutics | 53.47 Million USD | -1355.765% |
| Editas Medicine, Inc. | -99.52 Million USD | 882.206% |
| Verastem, Inc. | -62 Thousand USD | 1255767.742% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 97.065% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 2597.826% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -7652.579% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 4052.048% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 59.12% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 1817.626% |
| Evolus, Inc. | 140.52 Million USD | -454.0% |
| Adicet Bio, Inc. | -6.09 Million USD | 12866.71% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 1013.577% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 93.111% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -965.48% |
| FibroGen, Inc. | 128.9 Million USD | -503.949% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 77.532% |
| OPKO Health, Inc. | 318.12 Million USD | -144.718% |
| Homology Medicines, Inc. | -7.22 Million USD | 10869.318% |
| Geron Corporation | -123.5 Million USD | 730.36% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 48.711% |
| Exelixis, Inc. | 1.75 Billion USD | 55.707% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 266714.384% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 295.217% |
| Zoetis Inc. | 5.83 Billion USD | 86.656% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -218.365% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -257686.093% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 90.955% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 257035.314% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -63.59% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -22.236% |
| Blueprint Medicines Corporation | 236.58 Million USD | -229.065% |
| Insmed Incorporated | 239.63 Million USD | -224.875% |
| TG Therapeutics, Inc. | 219.1 Million USD | -255.311% |
| Incyte Corporation | 3.44 Billion USD | 77.373% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -126.378% |